Doncaster Pharma Limited has notified the MHRA of a Braille embossing error on outer packaging for certain parallel imported batches of Hiprex 1g tablets (methenamine hippurate). The embossed Braille incorrectly states the strength as 1mg rather than 1g, though all printed text correctly shows 1g. Five batches are affected, distributed between October 2025 and March 2026, all expiring April 2028. The MHRA has classified this as a Class 4 defect and is not recalling the affected products as they remain within specification with no quality issues. Healthcare professionals are advised to explain the error to patients who rely solely on Braille when reading medicine cartons.